دورية أكاديمية
Tc-99m-tamoxifen: A novel diagnostic imaging agent for estrogen receptor-expressing breast cancer patients
| العنوان: | Tc-99m-tamoxifen: A novel diagnostic imaging agent for estrogen receptor-expressing breast cancer patients |
|---|---|
| المؤلفون: | Anupriya Chhabra, Uma Sharma, Rajender Kumar, Ishita Laroiya, Alka Bhatia, Vijayta Chadha, Rakhee Vatsa, Deepti Upadhyay, Komalpreet Kaur, Amanjit Bal, Gurpreet Singh, Bhagwant Rai Mittal, Jaya Shukla |
| المصدر: | Diagnostic and Interventional Radiology, Vol 28, Iss 3, Pp 275-284 (2022) |
| بيانات النشر: | Galenos Publishing House, 2022. |
| سنة النشر: | 2022 |
| المجموعة: | LCC:Medical physics. Medical radiology. Nuclear medicine |
| مصطلحات موضوعية: | Medical physics. Medical radiology. Nuclear medicine, R895-920 |
| الوصف: | PURPOSEThe aim of the study was to radiolabel, characterize, and perform in vitro and in vivo assessment of Technetium-99m (Tc-99m) tamoxifen for screening ER expressing lesions in breast cancer patients.METHODSIn this study, tamoxifen has been radiolabeled with Tc-99m via Tc-99m-tricarbonyl core. The characterization and quality control tests of Tc-99m-tamoxifen were performed. In vitro recep- tor binding and blocking studies were performed in both positive control (MCF-7) and negative control cell lines (MDA-MB-231). Normal biodistribution studies were performed in female Wistar albino rats. The pilot clinical studies were performed in 4 ER-expressing breast cancer patients. Of the 4 patients, 1 was on tamoxifen therapy. All 4 patients had also undergone Fluorine-18 fluorodeoxyglucose (F-18-FDG) positron emission tomography/computed tomography.RESULTSTamoxifen was radiolabeled with Tc-99m via Tc-99m-tricarbonyl core with more than 95% radio- chemical yield. Mass spectra showed a peak corresponding to the molecular weight of Tc-99m- tricarbonyl and Tc-99m-tamoxifen. The site of binding of Tc-99m-tricarbonyl with tamoxifen was determined by proton nuclear magnetic resonance. The Tc-99m-tamoxifen showed 30% binding with MCF-7 and only 1%-2% receptor binding with MDA-MB-231 cell lines. Also, the percentage of receptor binding was drastically reduced (up to 72%) when ER was saturated with 50 times the excess molar ratio of unlabeled tamoxifen. In a pilot patient study, Tc-99m-tamoxifen uptake was observed in primary and metastatic lesions. However, no uptake was observed in a patient who was on tamoxifen therapy. The uptake of F-18-FDG was noted in all the patients.CONCLUSIONTamoxifen was radiolabeled with an in-house-synthesized Tc-99m-tricarbonyl core. The radio- labeled complex has been characterized and evaluated for receptor specificity in in vitro and in vivo studies. Also, this is the first clinical study using Tc-99m-tamoxifen for imaging ER. More patients need to be evaluated to further explore the role of Tc-99m-tamoxifen in ER-expressing lesions. |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1305-3825 1305-3612 |
| العلاقة: | http://www.dirjournal.org/archives/archive-detail/article-preview/tc-99m-tamoxifen-a-novel-diagnostic-imaging-agent-/53714Test; https://doaj.org/toc/1305-3825Test; https://doaj.org/toc/1305-3612Test |
| DOI: | 10.5152/dir.2022.201051 |
| الوصول الحر: | https://doaj.org/article/9508b177f5da4725a5e71142cf2c3bc8Test |
| رقم الانضمام: | edsdoj.9508b177f5da4725a5e71142cf2c3bc8 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 13053825 13053612 |
|---|---|
| DOI: | 10.5152/dir.2022.201051 |